Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 134, Issue 12, 2008, Pages 1316-1323

  Lee, Dong Wook ^a,b   Anderson, Mary E ^a   Wu, Shu ^a   Lee, John H ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b Chungbuk National University   (South Korea)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; PROTEIN E6; PROTEIN E7; RECOMBINANT VACCINE; VIRUS VACCINE;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CELL TRANSFORMATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; GENE INSERTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VITRO GENE TRANSFER; IN VIVO STUDY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; SQUAMOUS CELL CARCINOMA; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL LINE; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS;

EID: 58149240026     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2008.507     Document Type: Article

References (51)

1. Johnson N. Tobacco use and oral cancer: a global perspective. J Dent Educ. 2001;65(4):328-329.
2. Smith EM, Ritchie JM, Summersgill KF, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancer. Int J Cancer. 2004;108(5):766-772.
3. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475.
4. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer. 2003;104(3):336-344.
5. Hoffman HT, Karnell LH, Funk GF, Robinson RA, Menck HR. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124(9):951-962.
6. Ioka A, Tsukuma H, Ajiki W, Oshima A. Trends in head and neck cancer incidence in Japan during 1965-1999. Jpn J Clin Oncol. 2005;35(1):45-47.
7. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500-1510.
8. Cobo F, García C, Talavera P, Bravo J, Cabrera C, Concha A. Human papillomavirus associated with papillary squamous cell carcinoma of the oropharynx in a renal transplant recipient. Infection. 2006;34(3):176-180.
9. Scheffner M, Werness BA, Huibregste JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129-1136.
10. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papilloma virus E6 proteins. J Virol. 1994;68(7):4262-4273.
11. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 1996;380(6569):79-82.
12. Liu Y, Chen JJ, Gao O, et al. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol. 1999;73(9):7297-7307.
13. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934-937.
14. Münger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451-11460.
15. Helt AM, Funk JO, Galloway DA. Incativation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J Virol. 2002;76(20):10559-10568.
16. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Dürr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene. 1996;13(11):2323-2330.
17. Vousden KH, Lu X. Love or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594-604.
18. Rheinwald JG, Hahn WC, Ramsey MR, et al. A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol. 2002;22(14):5157-5172.
19. Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine. 2007;25(16):3001-3006.
20. Gambhira R, Gravitt PE, Bossis I, Stern PL, Viscidi RP, Roden RB. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res. 2006;66(23):11120-11124.
21. Ault KA. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Obstet Gynecol Surv. 2006;61(6)(suppl 1):S26-S31.
22. Berry JM, Palefsky JM. A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci. 2003;8:s333-s345.
23. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
24. Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingerhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck Surg. 2007;133(5):495-502.
25. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998;95(5):2509-2514.
26. Henry MD, Silva MD, Wen S, et al. Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients. Prostate. 2005;65(4):347-354.
27. Nasu Y, Saika T, Ebara S, et al. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther. 2007;15(4):834-840.
28. Mossoba ME, Medin JA. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines. 2006;5(5):717-732.
29. Hara H, Kobayashi A, Yoshida K, et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci. 2007;98(3):455-463.
30. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both toll-like receptor-dependent and -independent pathways. J Virol. 2007;81(7):3170-3180.
31. Lee JH, Yi SM, Anderson ME, et al. Propagation of infectious human papillomavirus type 16 by using an adenovirus and Cre/LoxP mechanism. Proc Natl Acad Sci U S A. 2004;101(7):2094-2099. doi:10.1073/pnas.0308615100.
32. Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh MJ. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J Clin Invest. 1998;102(1):184-193.
33. Smahel M, Síma P, Ludvíková V, Marinov I, Pokorná D, Vonka V. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine. 2003;21(11-12):1125-1136.
34. Ashrafi GH, Tsirimonaki E, Marchetti B, et al. Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene. 2002;21(2):248-259.
35. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007;121(11):2465-2472.
36. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer. 2003;107(3):394-400.
37. Hoffmann TK, Bier H, Whiteside TL. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2004;53(12):1055-1067.
38. Monji M, Senju S, Nakatsura T, et al. Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun. 2002;294(3):734-741.
39. Kao H, Marto JA, Hoffmann TK, et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med. 2001;194(9):1313-1323.
40. Kienstra MA, Neel HB, Strome SE, Roche P. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck. 2003;25(6):457-463.
41. Tindle RW, Frazer IH. Immune response to human papillomavirus-specific immunization. Curr Top Microbiol Immunol. 1994;186:217-253.
42. Bosch FX, Rohan T, Schneider A, et al. Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference. J Clin Pathol. 2001;54(3):163-175.
43. Hamilton-Easton A, Eichelberger M. Virus-specific antigen presentation by different subsets of cells from lung and mediastinal lymph node tissues of influenza virus-infected mice. J Virol. 1995;69(10):6359-6366.
44. Revaz V, Zurbiggen R, Moser C, et al. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res. 2007;76(1):75-85.
45. Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology. 1998;252(1):39-45.
46. Koutsky LA, Ault KA, Wheeler CM, et al; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-1651.
47. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-720.
48. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92(4):805-813.
49. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg. 2001;125(1):1-9.
50. Andrews DM, Maraskovsky E, Smyth MJ. Cancer vaccines for established cancer: how to make them better? Immunol Rev. 2008;222:242-255.
51. Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001;61(9):3689-3697.